Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 25512476.
- Also identified by DOI 10.3899/jrheum.141042.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Subcutaneous (SC) abatacept (ABA) is comparable to intravenous (IV) formulation in terms of efficacy and safety profile. Our work analyzed the switch to SC formulation from IV administration in patients with rheumatoid arthritis. Fifty-one patients treated with SC ABA were included. Clinical data were obtained from clinical charts. Fourteen patients relapsed and needed to return to the IV administration. Neither clinical and laboratory features nor the previous therapies were identified as risk factors for SC formulation inefficacy. Disease activity decreased after the return to IV infusions. SC ABA showed a risk of relapse in 27% of cases. The reinsertion of the IV administration quickly reinstated disease control.
Medical subject headings
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Immunoconjugates